You are here: Industry Insights > COMIRNATY

News List

EMA approves Pfizer-BioNTech COVID-19 vaccine for young children PharmaTimes
November 29, 2021
The Food and Drug Administration (FDA) granted approval for emergency use of the Comirnaty vaccine in children in October 2021.
FDA authorises Comirnaty® for emergency use in five to 11 year olds EuropeanPharmaceuticalReview
November 02, 2021
The US Food and Drug Administration (FDA) authorised the emergency use of the COVID-19 Vaccine Comirnaty® for the prevention of COVID-19 to include children five through 11 years of age.
Vaxzevria has similar safety profile to mRNA COVID-19 vaccines, finds study europeanpharmaceuticalreview
July 29, 2021
New studies show rates of blood clots were similar following vaccination with Vaxzevria and Comirnaty®, plus rates of rare blood clots are lower after the second Vaxzevria dose.
COVID-19 vaccines highly effective against hospitalisation by Delta variant europeanpharmaceuticalreview
June 22, 2021
An analysis shows Comirnaty® and the COVID-19 Vaccine AstraZeneca are both over 90 percent effective in preventing hospitalisation from the Delta variant.
Pharmacovigilance Risk Assessment Committee meeting highlights, June 2021 europeanpharmaceuticalreview
June 17, 2021
The European Medicines Agency (EMA)’s drug safety committee (PRAC) concluded three safety signal reviews, two for COVID-19 interventions, at its June meeting.
Comirnaty® COVID-19 vaccine protects against multiple viral variants europeanpharmaceuticalreview
June 16, 2021
Laboratory study shows the blood sera of people vaccinated against COVID-19 with Comirnaty® can neutralise at least six viral variants including three variants of concern.
Pfizer Covid-19 vaccine approved for adolescents in the UK pharmaceutical-technology
June 07, 2021
The approval of Pfizer and BioNTech’s Covid-19 vaccine COMIRNATY in the UK has been expanded to include individuals between 12 and 15 years of age.
EMA recommends first COVID-19 vaccine for children aged 12 to 15 europeanpharmaceuticalreview
June 03, 2021
The EMA is recommending that the Comirnaty® COVID-19 vaccine’s indication be extended to include children aged 12 to 15 years.
EU authorises Pfizer-BioNTech Covid-19 vaccine in adolescents pharmaceutical-technology
May 31, 2021
Pfizer and BioNTech have received expanded Conditional Marketing Authorization (CMA) in the European Union (EU) for their Covid-19 vaccine, Comirnaty, to include people aged 12 to 15 years.
EC to procure 1.8 billion doses of Pfizer-BioNTech’s Covid-19 vaccine pharmaceutical-technology
May 24, 2021
The European Commission (EC) has signed a new contract with BioNTech and Pfizer to procure additional 1.8 billion doses of their Covid-19 vaccine, Comirnaty, between this year end to 2023.

Previous page 1 2 3 Next page